Delivery Order SPE2DB24D2106-SPE2DB25FAWHM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,735.58 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose in 2-pen/mL formulation on August 25, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 26, 2025, represents a pharmaceutical supply requirement with performance taking place in Conshohocken, Pennsylvania. The award was made without set-aside designation to DMS Pharmaceutical Group, a woman-owned small business...
- The Defense Logistics Agency awarded a delivery order valued at $4,200.08 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300 mg pen 2 ml on August 25, 2025, with completion expected by August 26, 2025. This firm fixed-price delivery order represents a specific pharmaceutical requisition issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, valued at $499.999 billion and extending through November 2026. The award carries no...
- On August 20, 2025, the Defense Logistics Agency awarded a delivery order valued at $10,461.10 to DMS Pharmaceutical Group Inc. for the supply of Cosentyx (secukinumab) 300 mg pen 2 mL injections. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The contract does not utilize a set-aside designation, and the pharmaceutical products will be...
- The Defense Logistics Agency awarded a $16.8K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cosentyx (secukinumab) 300 mg pen injections. The order, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed-price delivery under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million and valid through November...
- The Defense Logistics Agency awarded a firm fixed price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide Cosentyx (secukinumab) 300 mg/2 mL injectable pens. The contract has a potential value of $3,382.36 and a completion date of January 3, 2024. DMS Pharmaceutical Group is a pharmaceutical wholesaler that holds multiple federal contracts and Indefinite Delivery Vehicles (IDVs) to supply a variety of pharmaceutical and medical products to support...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,382.36, is for the delivery of Cosentyx (secukinumab) 300 mg pens to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
- This federal contract award is for the delivery of Cosentyx (secukinumab) 300 mg pens to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense (DoD). The contract, valued at $3,382.36, was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order with no set-aside designation, running from the award date of July 30, 2024 through the ultimate...
- This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The order is for the delivery of Cosentyx (secukinumab) 300 mg pens, with a completion date of January 12, 2024 and a potential value of $3,382.36. DMS Pharmaceutical Group is a leading pharmaceutical wholesaler that provides a wide range of brand name and generic prescription and over-the-counter drug supplies to the U.S. Department of...
- This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $16,911.80 contract is for the delivery of Cosentyx Unoready 300 mg pens to the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of October 23, 2024. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $13,456.01 by the Defense Logistics Agency (DLA) on August 13, 2025. The contract calls for the delivery of Cosentyx Unoready 300 mg pen 2ml pharmaceutical product to a location in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. This delivery order was issued without a set-aside designation,...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB25FAWHMDelivery Order
The Defense Logistics Agency awarded a $8,935.09 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose in 2 pen/mL formulation on September 8, 2025, with an ultimate completion date of September 9, 2025. This award carries no set-aside designation and represents performance at the vendor's location in Conshohocken, Pennsylvania. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, is positioned as a critical supplier within the federal pharmaceutical supply chain serving Department of Defense healthcare facilities. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.9 billion vehicle valid through November 2026. The IDC enables DLA to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support military health facilities nationwide and worldwide. Cosentyx, a biologic immunosuppressant used primarily for autoimmune conditions, represents one of the specialized pharmaceutical products available through this extensive contract vehicle that has consistently demonstrated DMS Pharmaceutical Group's capability to deliver high-value therapeutic agents to federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 9/8/25 |